An FDA-approved GHRH analogue specifically indicated for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.
Sourced from Ascension Peptides. Verified purity, third-party tested. COA included.
Buy Now →Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), the hypothalamic peptide that stimulates the pituitary gland to produce and secrete growth hormone. It is the active pharmaceutical ingredient in Egrifta, a prescription medication manufactured by Theratechnologies Inc. and approved by the U.S. Food and Drug Administration in November 2010 for the treatment of excess abdominal fat (lipodystrophy) in HIV-infected patients. It is the only GHRH analog to achieve full FDA approval for a human therapeutic indication.
The key structural feature that distinguishes tesamorelin from native GHRH(1-44) — the naturally occurring form of the hypothalamic hormone — is the addition of a trans-3-hexenoic acid moiety attached to the N-terminus of the peptide chain. This modification was engineered by Theratechnologies specifically to address a major pharmacological limitation of native GHRH: rapid degradation by dipeptidyl peptidase IV (DPP-IV), an enzyme found in plasma and at vascular endothelium that cleaves the second amino acid from the N-terminus of GHRH, instantly inactivating the peptide. The trans-3-hexenoic acid group sterically protects the peptide bond targeted by DPP-IV, extending the plasma half-life of tesamorelin substantially compared to unmodified GHRH.
HIV-associated lipodystrophy is a syndrome characterized by abnormal redistribution of body fat, typically involving loss of fat from the face, limbs, and buttocks alongside pathological accumulation of visceral adipose tissue (VAT) in the abdominal region. This syndrome affects a significant proportion of HIV-positive individuals, particularly those on antiretroviral therapy, and is associated with increased cardiovascular risk, metabolic dysfunction, and significant psychological impact due to the visible body changes. Tesamorelin’s approval in this context was based on two pivotal Phase III randomized controlled trials demonstrating significant reductions in visceral fat measured by CT scan over 26 weeks of treatment.
Beyond the FDA-approved indication, tesamorelin has become one of the most extensively researched peptide compounds in clinical medicine, with ongoing and published studies examining its effects on triglycerides, cognitive function in aging populations, non-alcoholic fatty liver disease, and its potential utility outside the HIV context. Explore tesamorelin alongside other GHRH analogs in our peptide database.
Tesamorelin acts as a full agonist at the GHRH receptor (GHRH-R), a G protein-coupled receptor expressed on somatotroph cells in the anterior pituitary gland. When tesamorelin binds GHRH-R, it activates adenylyl cyclase through Gs protein coupling, increasing intracellular cAMP, activating protein kinase A, and ultimately stimulating both the synthesis of new GH and the exocytotic release of stored GH from secretory granules. The trans-3-hexenoic acid modification extends the compound’s plasma half-life by protecting against DPP-IV degradation, but the receptor-binding domain and mechanism of GH stimulation are functionally equivalent to native GHRH. A critical feature of tesamorelin’s mechanism is that it works by stimulating endogenous GH secretion rather than delivering GH directly. This means the body’s own regulatory mechanisms — somatostatin release, IGF-1 feedback loops, and other homeostatic signals — remain partially intact, limiting the extent of GH elevation and preserving pulsatile secretory dynamics. Exogenous hGH administration bypasses these feedback controls entirely, which is why hGH use produces a flat, non-pulsatile GH exposure profile that is mechanistically distinct from normal physiology and associated with a more problematic side effect profile than tesamorelin.
The increased GH secretion stimulated by tesamorelin travels to the liver and other target tissues, where it stimulates the production of IGF-1. IGF-1 is the primary mediator of many of GH’s anabolic and metabolic effects, including changes in body composition. In adipose tissue, the GH/IGF-1 axis regulates multiple aspects of fat cell biology, including lipolysis, adipogenesis, and the expression of lipolytic enzymes. Visceral adipose tissue, which accumulates abnormally in HIV lipodystrophy and metabolic syndrome, has a distinct cellular biology from subcutaneous fat — visceral adipocytes have higher GH receptor density and are particularly sensitive to GH-mediated lipolysis. This tissue-specific sensitivity is thought to underlie tesamorelin’s selective action on visceral rather than subcutaneous fat. The preferential reduction of VAT has metabolic significance beyond aesthetics: visceral fat is metabolically active in ways that subcutaneous fat is not, releasing adipokines and free fatty acids that drive insulin resistance, dyslipidemia, and systemic inflammation. Reducing VAT therefore has downstream metabolic benefits that extend well beyond the fat loss itself.
A mechanistically important distinction between tesamorelin and exogenous growth hormone administration is the preservation of hypothalamic-pituitary regulatory feedback when using a GHRH analog versus hGH itself. The somatotropic axis is controlled by a negative feedback loop in which elevated GH and IGF-1 stimulate hypothalamic release of somatostatin, which then inhibits GH secretion from the pituitary. When exogenous hGH is administered, this feedback is activated in an attempt to normalize GH signaling, but since the source of GH is exogenous, the feedback cannot reduce GH levels below the pharmacologically maintained baseline. With tesamorelin, the GH stimulation signal comes through the natural GHRH receptor, and the pituitary somatotrophs and hypothalamic somatostatin system can still modulate the response. This means that tesamorelin’s GH-elevating effect has a natural ceiling imposed by the body’s own regulatory systems, and the IGF-1 elevation produced is generally more physiologically bounded than with direct hGH injection. Clinical trial data bears this out: IGF-1 levels in tesamorelin-treated patients typically increase into the upper normal range or modestly above, rather than the supraphysiological levels seen with therapeutic hGH doses.
The clinical evidence base that secured tesamorelin’s FDA approval consists primarily of two Phase III randomized, double-blind, placebo-controlled trials conducted in HIV-positive adults with excess abdominal fat. Study 1 (NCT00433940) and Study 2 (NCT00435136) together enrolled several hundred participants randomized to tesamorelin 2 mg subcutaneously daily or placebo for 26 weeks, with a maintenance phase extending to 52 weeks. The primary endpoint — change in visceral adipose tissue measured by CT scan at 26 weeks — showed statistically significant and clinically meaningful reductions in the tesamorelin group: approximately 18% reduction in VAT from baseline versus essentially no change in the placebo group. This is a large effect size for a pharmaceutical intervention targeting visceral fat. Secondary endpoints including trunk fat percentage, waist circumference, patient-reported body image scores, and quality of life measures all showed significant improvements in the treated group. Triglycerides, measured as a secondary metabolic endpoint, showed meaningful reductions — particularly relevant given the cardiovascular risk profile of the HIV population. IGF-1 levels increased in treated patients, and the safety monitoring showed that most patients had IGF-1 values within or near the normal physiological range, with a small proportion having transiently elevated levels that normalized with continued treatment or brief dose interruption.
The lipid metabolism effects of tesamorelin have received attention both as secondary findings from the HIV lipodystrophy trials and as the subject of focused investigation. HIV-positive patients on antiretroviral therapy, particularly older regimens using protease inhibitors, have high rates of hypertriglyceridemia as part of the lipodystrophy syndrome. The FDA-approved prescribing information for Egrifta includes triglyceride reduction as a documented metabolic effect. The mechanism for tesamorelin’s triglyceride-lowering action is thought to involve both direct effects of elevated GH/IGF-1 on hepatic lipid metabolism and secondary effects of visceral fat reduction — since visceral adipocytes contribute significantly to portal free fatty acid flux, which drives hepatic triglyceride synthesis. Research in non-HIV populations with metabolic syndrome and elevated triglycerides has also examined tesamorelin, with preliminary findings suggesting the triglyceride benefit extends beyond the HIV context, though this has not been the subject of a completed phase III program outside of HIV lipodystrophy.
A growing and scientifically compelling body of research has examined tesamorelin’s effects on cognitive function in older adults, motivated by evidence that the age-related decline in GH and IGF-1 secretion contributes to age-associated cognitive changes. A double-blind, randomized trial by Friedman and colleagues published in 2013 in JAMA Neurology enrolled older adults (65+) without HIV and found that tesamorelin administration over 20 weeks produced significant improvements in cognitive composite scores, particularly in executive function and verbal memory domains, compared to placebo. These cognitive benefits were associated with — but not entirely explained by — changes in IGF-1 levels, suggesting both IGF-1-mediated and potentially direct GH-mediated contributions to cognitive outcomes. The mechanisms proposed include IGF-1’s known neurotrophic effects in the hippocampus and prefrontal cortex, modulation of amyloid precursor protein processing (relevant to Alzheimer’s disease biology), and potential effects on cerebral blood flow and synaptic plasticity. This cognitive aging research has sparked significant scientific interest and ongoing investigation into whether tesamorelin or GHRH analogs more broadly could be useful in addressing age-related cognitive decline — a much larger potential indication than HIV lipodystrophy.
HIV-associated lipodystrophy frequently co-occurs with non-alcoholic fatty liver disease (NAFLD), and research has examined whether tesamorelin’s reduction of visceral adiposity translates into liver fat reduction and improvement in NAFLD parameters. Studies using magnetic resonance spectroscopy to quantify liver fat content have found significant reductions in hepatic triglyceride content following tesamorelin treatment, which is mechanistically coherent given the role of visceral fat in driving hepatic lipid accumulation through portal free fatty acid delivery. Liver enzyme elevations (ALT, AST) — surrogate markers of hepatic inflammation in NAFLD — have also shown improvement in some tesamorelin-treated cohorts. This research area is notable because NAFLD is an enormously prevalent condition in the general population (affecting an estimated 25-30% of adults in developed countries), and effective pharmacological treatments remain limited. Tesamorelin’s NAFLD data, while mostly generated in HIV populations or small proof-of-concept studies, has prompted interest in whether it could address liver fat in metabolic NAFLD more broadly.
An important clinical observation from the tesamorelin trial program is that the visceral fat reductions achieved during active treatment are largely reversed within weeks to months of discontinuation. This was examined in the 52-week maintenance phase of the pivotal trials, where a randomized subset switched from tesamorelin to placebo after the initial 26-week period and showed return of VAT levels toward baseline. This finding has two implications: first, it establishes that tesamorelin’s effects are mediated by the ongoing pharmacological activity of the compound rather than by permanent structural changes to adipose tissue, and second, it means that ongoing treatment is required to maintain the benefit. This is similar to what is observed with other metabolically active compounds including hGH itself. Understanding the reversibility of effects is important for research protocols and for interpreting the mechanism of action — tesamorelin is modulating a dynamic, ongoing biological process rather than inducing lasting anatomical change.
The FDA-approved dose of tesamorelin for HIV-associated lipodystrophy is 2 mg administered once daily by subcutaneous injection. This dose was selected based on Phase II dose-finding studies that established 2 mg as providing the optimal balance of efficacy and tolerability. The injection is typically given in the abdominal region, rotating sites to minimize local tissue reactions. Tesamorelin comes as a lyophilized powder that must be reconstituted with the provided sterile water for injection immediately before use, as the reconstituted solution has a limited stability window. Administration is timed to occur at approximately the same time each day, preferably in the evening before sleep to align with the natural nocturnal pattern of GHRH release, though the prescribing information does not specify a required time of day. Our peptide calculators include reconstitution and dosing reference tools.
Clinical research studies investigating tesamorelin for cognitive function, NAFLD, and other non-HIV applications have used the same 2 mg daily dose established for HIV lipodystrophy, given that this dose has the most complete safety characterization and the Phase II dose-finding work identified it as pharmacologically appropriate for GH-stimulating purposes. Some studies have examined 1 mg doses in populations expected to have heightened GH responses (such as older adults with preserved GH axis sensitivity) to allow for adequate IGF-1 elevation without the risk of excessive levels. The research literature has not identified a substantially superior efficacy dose above 2 mg for the endpoints studied, and higher doses increase the risk of fluid retention, arthralgia, and other GH-excess effects.
The prescribing information for Egrifta specifies periodic monitoring of IGF-1 levels during tesamorelin treatment to confirm that levels are not reaching supraphysiological ranges, which could increase theoretical cancer risk and would produce the side effect profile of GH excess. Fasting glucose and HbA1c monitoring is also recommended given that elevated GH can impair insulin sensitivity over time. In clinical practice, assessments at 3-month intervals during the first year are commonly used. Patients with diabetes or prediabetes require more careful glucose monitoring. The monitoring requirements reflect the pharmacological profile of a compound that genuinely elevates GH and IGF-1 — the clinical utility requires that this elevation stay within a range where benefits outweigh risks.
The FDA label for tesamorelin includes several important contraindications: active malignancy or history of malignancy (given that IGF-1 can support tumor growth), pituitary tumor or other causes of structural GH deficiency (where the pituitary response to GHRH would be absent or unpredictable), pregnancy (no human safety data; animal studies showed harm), and hypersensitivity to tesamorelin or its excipients. Caution is warranted in patients with diabetes because of glucose impairment risks, and in patients with fluid retention conditions because of GH’s sodium-retaining effects. These contraindications define important exclusion criteria for research protocols and reflect the mechanistic consequences of sustained GH/IGF-1 elevation.
The most frequently reported adverse effects in tesamorelin clinical trials include injection site reactions (erythema, pruritus, pain at injection site), which occurred in a significant minority of patients but were generally mild and did not lead to discontinuation in most cases. Systemic adverse effects related to GH excess were the next most clinically significant category: fluid retention manifesting as peripheral edema, arthralgia (joint pain), and myalgia (muscle pain) occurred more frequently in tesamorelin-treated patients than placebo. These GH-class effects are dose-related and generally resolve with dose reduction or treatment interruption. Glucose metabolism abnormalities — increased fasting glucose, impaired glucose tolerance — were observed in some patients, more commonly in those with pre-existing metabolic risk factors. The magnitude of glucose impairment was modest in most cases and did not reach the level of newly developed diabetes in the trial populations, though glucose monitoring is still a standard of care recommendation during treatment.
The theoretical concern most extensively discussed in tesamorelin’s regulatory and clinical literature is the relationship between sustained IGF-1 elevation and cancer risk. IGF-1 is a mitogenic peptide that stimulates cell proliferation and inhibits apoptosis in many tissue types, and epidemiological research has found associations between chronically elevated IGF-1 levels and increased risk of certain cancers including breast, prostate, and colorectal cancer. This is why the prescribing information includes malignancy as a contraindication and recommends IGF-1 monitoring. In the pivotal trials, tesamorelin did not produce a statistically detectable increase in cancer incidence, but the trials were not sized or powered to detect modest cancer risk increases, and the follow-up duration (up to 52 weeks) is insufficient to characterize long-term cancer risk. The post-marketing surveillance required by FDA approval will ultimately provide more informative long-term safety data as the compound is used commercially. Researchers and clinicians must weigh this theoretical risk against the established cardiovascular risk of visceral adiposity when making treatment decisions.
Tesamorelin’s drug interaction profile is primarily mediated through its effects on GH and IGF-1 rather than through direct pharmacokinetic interactions with drug-metabolizing enzymes. GH is known to influence the metabolism of certain cytochrome P450 substrates, including glucocorticoids (GH counteracts cortisol’s effects) and anticonvulsants. In the HIV context, interactions with antiretroviral agents are a specific concern — protease inhibitors in particular can affect GH secretion and metabolism, and the combination of tesamorelin with a drug-affected GH axis requires careful consideration. In elderly populations — a key demographic for the cognitive aging research — age-related changes in GH axis sensitivity mean that standard doses may produce larger or more variable IGF-1 responses than in younger adults, necessitating more careful dose titration and monitoring. Our AI peptide coach can provide general research background on tesamorelin safety considerations for informational purposes.
This is the most important conceptual distinction for anyone researching tesamorelin. Growth hormone itself is a 191 amino acid protein that directly activates GH receptors throughout the body. Tesamorelin is a 44 amino acid GHRH analog that stimulates the pituitary to secrete GH — it works upstream of GH itself. The practical consequences of this distinction are significant: tesamorelin preserves pulsatile GH release and maintains negative feedback regulation, whereas exogenous hGH produces a continuous, non-pulsatile, unregulated GH exposure. The result is that tesamorelin produces a more physiologically normal pattern of GH signaling with a better-bounded IGF-1 elevation, fewer metabolic side effects (particularly less glucose impairment), and no suppression of endogenous GH axis function. When tesamorelin is discontinued, the GH axis returns to its prior baseline; long-term exogenous hGH use can suppress endogenous GH production in ways that may take months to recover.
Tesamorelin is FDA-approved specifically for HIV-associated lipodystrophy, which is its only approved indication. Using it outside that indication (off-label use) is a physician’s prerogative in clinical practice, but insurance coverage would typically not apply and the regulatory framework differs from the approved indication. Research studies have examined tesamorelin in non-HIV populations — the cognitive aging research is a prominent example — and these studies use tesamorelin under IND (Investigational New Drug) applications with full research ethics oversight. The scientific rationale for investigating tesamorelin in non-HIV contexts is sound, but the evidence base for non-HIV applications is at an earlier stage than the lipodystrophy data.
The selectivity for visceral fat reduction reflects both GH receptor biology and the metabolic differences between fat depots. Visceral adipocytes — the fat cells that pack around the internal organs in the abdominal cavity — have higher GH receptor expression than subcutaneous fat cells, making them more sensitive to the lipolytic signals generated by GH. They also have higher lipolytic enzyme activity at baseline and a more active metabolic turnover rate. When GH signaling is increased by tesamorelin, the visceral compartment responds more robustly to the lipolytic stimulation. Subcutaneous fat is metabolically less active and less GH-responsive, so it shows less reduction. This selectivity is actually a clinical advantage since visceral fat drives metabolic disease risk disproportionately.
This has been directly studied in the maintenance phase of the pivotal trials. Patients who switched from tesamorelin to placebo after 26 weeks showed return of VAT toward (though not completely to) baseline over the subsequent 26-week observation period. This reversal is expected given that tesamorelin’s effects depend on ongoing GH stimulation — without the continued pharmacological stimulus, the GH axis returns to its prior secretory pattern, and the adipocyte biology reverts accordingly. For patients using tesamorelin for its approved HIV lipodystrophy indication, this means the drug needs to be continued to maintain the benefit, which is not unusual for metabolic interventions.
Based on the prescribing information and clinical practice guidelines, the key monitoring parameters are: IGF-1 levels (to confirm elevation is within the target range and not supraphysiological), fasting glucose and HbA1c (to detect glucose impairment), periodic reassessment of visceral fat response (often by waist circumference measurement with periodic CT scan if clinically indicated), and clinical assessment for fluid retention, joint pain, and other GH-excess symptoms. The monitoring schedule should be individualized based on patient risk factors, but quarterly assessments during the first year are a common framework.
In the United States, tesamorelin (Egrifta) is FDA-approved only for HIV-associated lipodystrophy, but physicians can prescribe it off-label for other indications at their clinical discretion. In practice, off-label prescriptions are rare outside academic or research settings because insurance coverage is limited to the approved indication and because the off-label evidence base, while interesting, has not yet been sufficient to drive widespread clinical adoption. Several research groups are actively pursuing additional regulatory indications, particularly for NAFLD and cognitive aging, which could expand the approved use profile if trials succeed.
Sermorelin is a shorter GHRH analog (GHRH 1-29) that was previously FDA-approved for pediatric GH deficiency diagnosis but is no longer available as a pharmaceutical product. Both tesamorelin and sermorelin act at the GHRH receptor and stimulate pulsatile GH release. The key differences are: tesamorelin’s trans-3-hexenoic acid modification provides greater DPP-IV resistance and extended half-life compared to sermorelin; tesamorelin has substantially more clinical trial data including two Phase III RCTs; and tesamorelin has an active FDA approval while sermorelin’s pharmaceutical approval is defunct. Research peptide compounding pharmacies prepare sermorelin for off-label research use. For detailed comparative profiles, our peptide database has entries on both compounds.
This is a scientifically legitimate research question, and the mechanistic rationale suggests it could — GH’s lipolytic effects on visceral adipose tissue don’t require HIV as a precondition, and the biology of visceral fat accumulation in metabolic syndrome shares features with HIV lipodystrophy. However, the clinical trial data outside the HIV context is much more limited, the absolute GH deficiency is not present in most obese individuals (though relative GH hyposecretion is common with obesity), and the regulatory and practical barriers to accessing tesamorelin outside its approved indication are significant. This remains an active area of research interest rather than an established clinical application.
Disclaimer: This information is for research and educational purposes only. It is not medical advice. Consult a qualified healthcare professional before using any peptide.